Vasculitis & polymyalgia rheumatica
Long-term outcomes and prognosis of mixed cryoglobulinaemia: a European multicentre study of 1294 patients
Authors' conclusion
HCV was for long considered a poor prognosis factor in CryoVas, and now those secondary to autoimmune conditions seem to evolve with a more severe course, notably carrying a higher lymphoma risk.
Study context
- Population
- Patients presenting with all-cause mixed cryoglobulinaemia vasculitis (CryoVas), Europe (EuroCryo)EuroCryo cohort
- Participants
- 1,294 patients
- Outcome
- Long-term outcomes (severe events; event-free survival) and prognostic factors
Methodological detailsEuropean multicentre, multivariable model
- European multicentre
- Multivariable model
Main finding
As reported in the abstract
Severe events · median follow-up of 2.8 years
- Patients experiencing severe events
- 558
- Severe events
- 661
- Relapses
- 221
- Severe infections
- 52
- Lymphomas
- 45
Observational data: associations, not effects.
Further findings
Aetiology of CryoVas
- HCV
- 469 (36%)
- Essential forms
- n = 344, 26%
- Autoimmune conditions
- n = 302, 23%
- Sjögren's disease
- n = 268, 21%
Factors associated with lymphoma
- Post-2014 diagnosis, autoimmune aetiology, fever, fatigue and low C4
Original publication
Long-term outcomes and prognosis of mixed cryoglobulinaemia: a European multicentre study of 1294 patients. Rheumatology (Oxford). Published 18 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →